Medicare Program; Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, 23084-23085 [2023-07913]
Download as PDF
23084
Federal Register / Vol. 88, No. 72 / Friday, April 14, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1797–N]
Medicare Program; Meeting
Announcement for the Medicare
Advisory Panel on Clinical Diagnostic
Laboratory Tests
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces the
public meeting dates for the Medicare
Advisory Panel on Clinical Diagnostic
Laboratory Tests (the Panel) on
Wednesday, July 19, 2023 and
Thursday, July 20, 2023. The purpose of
the Panel is to advise the Secretary of
the Department of Health and Human
Services and the Administrator of the
Centers for Medicare & Medicaid
Services on issues related to clinical
diagnostic laboratory tests.
DATES: Meeting Dates: The virtual
meeting of the Panel is scheduled for
Wednesday, July 19, 2023 from 9:00
a.m. to 5:00 p.m., Eastern Daylight Time
(E.D.T.) and Thursday, July 20, 2023,
from 9:00 a.m. to 5:00 p.m., E.D.T. The
Panel is also expected to virtually
participate in the Clinical Laboratory
Fee Schedule (CLFS) Annual Public
Meeting for Calendar Year (CY) 2024 on
Thursday June 22, 2023 in order to
gather information and ask questions to
presenters. Notice of the CLFS Annual
Public Meeting for CY 2024 is published
elsewhere in this issue of the Federal
Register.
Deadline for Meeting Registration: All
stand-by speakers for the Panel meeting
must register electronically to our CDLT
Panel dedicated email box, CDLTPanel@
cms.hhs.gov by June 1, 2023.
Registration is not required for nonspeakers. The public may view this
meeting via webinar, or listen-only via
teleconference.
Webinar and Teleconference Meeting
Information: Teleconference dial-in
instructions, and related webinar details
will be posted on the meeting agenda,
which will be available on the CMS
website approximately 2 weeks prior to
the meeting at https://www.cms.gov/
Regulations-and-Guidance/Guidance/
FACA/AdvisoryPanelonClinical
DiagnosticLaboratoryTests.html. A
preliminary agenda is described in
section II of this notice.
ADDRESSES: The Panel meeting will be
held virtually and will not occur at the
campus of the Centers for Medicare &
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:45 Apr 13, 2023
Jkt 259001
Medicaid Services (CMS), Central
Building, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
FOR FURTHER INFORMATION CONTACT: The
CLFS Policy Team via email,
CDLTPanel@cms.hhs.gov; or Rasheeda
Arthur, (410) 786–3434. The CMS Press
Office, for press inquiries, (202) 690–
6145.
SUPPLEMENTARY INFORMATION:
I. Background
The Medicare Advisory Panel on
Clinical Diagnostic Laboratory Tests
(CDLTs) (the Panel) is authorized by
section 1834A(f)(1) of the Social
Security Act (the Act) (42 U.S.C.
1395m–1), as established by section
216(a) of the Protecting Access to
Medicare Act of 2014 (PAMA) (Pub. L.
113–93), enacted on April 1, 2014. The
Panel is subject to the Federal Advisory
Committee Act (FACA), as amended (5
U.S.C. Appendix 2), which sets forth
standards for the formation and use of
advisory panels.
Section 1834A(f)(1) of the Act directs
the Secretary of the Department of
Health and Human Services (the
Secretary) to consult with an expert
outside advisory panel established by
the Secretary, composed of an
appropriate selection of individuals
with expertise in issues related to
clinical diagnostic laboratory tests,
which may include the development,
validation, performance, and
application of such tests. Such
individuals may include molecular
pathologists, researchers, and
individuals with expertise in laboratory
science or health economics.
The Panel will provide input and
recommendations to the Secretary and
the Administrator of the Centers for
Medicare & Medicaid Services (CMS),
on the following:
• The establishment of payment rates
under section 1834A of the Act for new
clinical diagnostic laboratory tests,
including whether to use
‘‘crosswalking’’ or ‘‘gapfilling’’
processes to determine payment for a
specific new test.
• The factors used in determining
coverage and payment processes for
new clinical diagnostic laboratory tests.
• Other aspects of the payment
system under section 1834A of the Act.
A notice announcing the
establishment of the Panel and soliciting
nominations for members was
published in the October 27, 2014
Federal Register (79 FR 63919 through
63920). In the August 7, 2015 Federal
Register (80 FR 47491), we announced
membership appointments to the Panel
along with the first public meeting date
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
for the Panel, which was held on August
26, 2015. Subsequent meetings of the
Panel and membership appointments
were also announced in the Federal
Register.
II. Agenda
The Agenda for the July 19 and July
20, 2023 Panel meeting will provide for
discussion and comment on the
following topics as designated in the
Panel’s charter:
• Calendar Year (CY) 2024 Clinical
Laboratory Fee Schedule (CLFS) new
and reconsidered test codes, which will
be posted on the CMS website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ClinicalLab
FeeSched/Laboratory_Public_
Meetings.html.
• Other CY 2024 CLFS issues
designated in the Panel’s charter and
further described on our Agenda.
A detailed Agenda will be posted
approximately 2 weeks before the
meeting, on the CMS website at https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory
PanelonClinicalDiagnosticLaboratory
Tests.html. The Panel will make
recommendations to the Secretary and
the Administrator of CMS regarding
crosswalking and gapfilling for new and
reconsidered laboratory tests discussed
during the CLFS Annual Public Meeting
for CY 2024. The Panel will also provide
input on other CY 2024 CLFS issues that
are designated in the Panel’s charter and
specified on the meeting agenda.
III. Meeting Participation
This meeting is open to the public.
Stand-by speakers may participate in
the meeting via teleconference and
webinar. A stand-by speaker is an
individual who will speak on behalf of
a company or organization if the Panel
has any questions during the meeting
about technical information described
in the public comments or presentation
previously submitted or presented by
the organization or company at the
recent CLFS Annual Public Meeting for
CY 2023 on June 22, 2023. The public
may also view or listen-only to the
meeting via teleconference and webinar.
IV. Registration Instructions for Standby Speakers
Beginning May 1, 2023 and ending
June 27, 2023 at 5:00 p.m. E.D.T.,
registration to serve as a stand-by
speaker may be completed by sending
an email to the following resource box
CDLTPanel@cms.hhs.gov. The subject of
the email should state ‘‘Stand-by
Speaker Registration for CDLT Panel
Meeting.’’ In the email, all of the
E:\FR\FM\14APN1.SGM
14APN1
Federal Register / Vol. 88, No. 72 / Friday, April 14, 2023 / Notices
following information must be
submitted when registering:
• Stand-by Speaker name.
• Organization or company name.
• Email addresses that will be used
by the speaker in order to connect to the
virtual meeting.
• New or Reconsidered Code (s) for
which the company or organization you
are representing submitted a comment
or presentation.
Registration details may not be
revised once they are submitted. If
registration details require changes, a
new registration entry must be
submitted by the date specified in the
DATES section of this notice.
Additionally, registration information
must reflect individual- level content
and not reflect an organization entry.
Also, each individual may only register
one person at a time. That is, one
individual may not register multiple
individuals at the same time.
After registering, a confirmation email
will be sent upon receipt of the
registration. The email will provide
information to the speaker in
preparation for the meeting. Registration
is only required for stand-by speakers
and must be submitted by the deadline
specified in the DATES section of this
notice. Note: No registration is required
for participants who plan to view the
Panel meeting via webinar or listen via
teleconference.
V. Panel Recommendations and
Discussions
The Panel’s recommendations will be
posted approximately 2 weeks after the
meeting on the CMS website at https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory
PanelonClinicalDiagnosticLaboratory
Tests.html.
VI. Special Accommodations
Individuals viewing or listening to the
meeting who are hearing or visually
impaired and have special
requirements, or a condition that
requires special assistance, should send
an email to the resource box
(CDLTPanel@cms.hhs.gov). The
deadline for submitting this request is
listed in the DATES section of this notice.
ddrumheller on DSK120RN23PROD with NOTICES1
VII. Copies of the Charter
The Secretary’s Charter for the
Medicare Advisory Panel on CDLT’s is
available on the CMS website at https://
cms.gov/Regulations-and-Guidance/
Guidance/FACA/Advisory
PanelonClinicalDiagnosticLaboratory
Tests.html or you may obtain a copy of
the charter by submitting a request to
the contact listed in the FOR FURTHER
VerDate Sep<11>2014
17:45 Apr 13, 2023
Jkt 259001
INFORMATION CONTACT
section of this
notice.
VIII. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
The Administrator of CMS, Chiquita
Brooks-LaSure, having reviewed and
approved this document, authorizes
Evell J. Barco Holland, who is the
Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Dated: April 11, 2023.
Evell J. Barco Holland,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2023–07913 Filed 4–13–23; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1796–N]
Medicare Program; Public Meeting on
June 22, 2023 Regarding New and
Reconsidered Clinical Diagnostic
Laboratory Test Codes for the Clinical
Laboratory Fee Schedule for Calendar
Year 2024
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces a
public meeting to receive comments and
recommendations (including data on
which recommendations are based) on
the appropriate basis for establishing
payment amounts for new or
substantially revised Healthcare
Common Procedure Coding System
codes being considered for Medicare
payment under the Clinical Laboratory
Fee Schedule for calendar year 2024.
This meeting also provides a forum for
those who submitted certain
reconsideration requests regarding final
determinations made last year on new
test codes and for the public to provide
comment on the requests.
DATES:
CLFS Annual Public Meeting Date:
The virtual meeting is scheduled for
SUMMARY:
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
23085
Thursday, June 22, 2023 from 9:00 a.m.
to 5:00 p.m., E.D.T.
Deadline for Submission of
Presentations and Written Comments:
All presenters for the CLFS Annual
Public Meeting must register and submit
their presentations electronically to our
CLFS dedicated email box, CLFS_
Annual_Public_Meeting@cms.hhs.gov,
by June 1, 2023 at 5:00 p.m., E.D.T. All
written comments (non-presenter
comments) must also be submitted
electronically to our CLFS dedicated
email box, CLFS_Annual_Public_
Meeting@cms.hhs.gov, by June 1, 2023,
at 5:00 p.m., E.D.T. Any presentations or
written comments received after that
date and time will not be included in
the meeting and will not be reviewed.
Deadline for Submitting Requests for
Special Accommodations: Requests for
special accommodations must be
received no later than June 1, 2023 at
5:00 p.m. E.D.T.
Publication of Proposed
Determinations: We intend to publish
our proposed determinations for new
test codes and our proposed
determinations for reconsidered codes
(as described later in section II,
‘‘Format’’ of this notice) for CY 2024 by
early September 2023.
Deadline for Submission of Written
Comments Related to Proposed
Determinations: Comments in response
to the proposed determinations will be
due by early October 2023.
ADDRESSES: The CLFS Annual Public
Meeting will be held virtually and will
not occur at the campus of the Centers
for Medicare & Medicaid Services
(CMS), Central Building, 7500 Security
Boulevard, Baltimore, Maryland 21244–
1850.
Where to Submit Written Comments:
Interested parties should submit all
written comments on presentations and
proposed determinations electronically
to our CLFS dedicated email box, CLFS_
Annual_Public_Meeting@cms.hhs.gov
(the specific date for the publication of
these determinations and the deadline
for submitting comments regarding
these determinations will be published
on the CMS website).
FOR FURTHER INFORMATION CONTACT: The
CLFS Policy Team and submit all
inquiries to the CLFS dedicated email
box, CLFS_Annual_Public_Meeting@
cms.hhs.gov with the subject entitled
‘‘CLFS Annual Public Meeting Inquiry.’’
SUPPLEMENTARY INFORMATION:
I. Background
Section 531(b) of the Medicare,
Medicaid, and SCHIP Benefits
Improvement and Protection Act of
2000 (BIPA) (Pub. L. 106–554) required
E:\FR\FM\14APN1.SGM
14APN1
Agencies
[Federal Register Volume 88, Number 72 (Friday, April 14, 2023)]
[Notices]
[Pages 23084-23085]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07913]
[[Page 23084]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-1797-N]
Medicare Program; Meeting Announcement for the Medicare Advisory
Panel on Clinical Diagnostic Laboratory Tests
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the public meeting dates for the
Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the
Panel) on Wednesday, July 19, 2023 and Thursday, July 20, 2023. The
purpose of the Panel is to advise the Secretary of the Department of
Health and Human Services and the Administrator of the Centers for
Medicare & Medicaid Services on issues related to clinical diagnostic
laboratory tests.
DATES: Meeting Dates: The virtual meeting of the Panel is scheduled for
Wednesday, July 19, 2023 from 9:00 a.m. to 5:00 p.m., Eastern Daylight
Time (E.D.T.) and Thursday, July 20, 2023, from 9:00 a.m. to 5:00 p.m.,
E.D.T. The Panel is also expected to virtually participate in the
Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting for
Calendar Year (CY) 2024 on Thursday June 22, 2023 in order to gather
information and ask questions to presenters. Notice of the CLFS Annual
Public Meeting for CY 2024 is published elsewhere in this issue of the
Federal Register.
Deadline for Meeting Registration: All stand-by speakers for the
Panel meeting must register electronically to our CDLT Panel dedicated
email box, [email protected] by June 1, 2023. Registration is not
required for non-speakers. The public may view this meeting via
webinar, or listen-only via teleconference.
Webinar and Teleconference Meeting Information: Teleconference
dial-in instructions, and related webinar details will be posted on the
meeting agenda, which will be available on the CMS website
approximately 2 weeks prior to the meeting at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. A preliminary
agenda is described in section II of this notice.
ADDRESSES: The Panel meeting will be held virtually and will not occur
at the campus of the Centers for Medicare & Medicaid Services (CMS),
Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244-
1850.
FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team via email,
[email protected]; or Rasheeda Arthur, (410) 786-3434. The CMS
Press Office, for press inquiries, (202) 690-6145.
SUPPLEMENTARY INFORMATION:
I. Background
The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests
(CDLTs) (the Panel) is authorized by section 1834A(f)(1) of the Social
Security Act (the Act) (42 U.S.C. 1395m-1), as established by section
216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L.
113-93), enacted on April 1, 2014. The Panel is subject to the Federal
Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which
sets forth standards for the formation and use of advisory panels.
Section 1834A(f)(1) of the Act directs the Secretary of the
Department of Health and Human Services (the Secretary) to consult with
an expert outside advisory panel established by the Secretary, composed
of an appropriate selection of individuals with expertise in issues
related to clinical diagnostic laboratory tests, which may include the
development, validation, performance, and application of such tests.
Such individuals may include molecular pathologists, researchers, and
individuals with expertise in laboratory science or health economics.
The Panel will provide input and recommendations to the Secretary
and the Administrator of the Centers for Medicare & Medicaid Services
(CMS), on the following:
The establishment of payment rates under section 1834A of
the Act for new clinical diagnostic laboratory tests, including whether
to use ``crosswalking'' or ``gapfilling'' processes to determine
payment for a specific new test.
The factors used in determining coverage and payment
processes for new clinical diagnostic laboratory tests.
Other aspects of the payment system under section 1834A of
the Act.
A notice announcing the establishment of the Panel and soliciting
nominations for members was published in the October 27, 2014 Federal
Register (79 FR 63919 through 63920). In the August 7, 2015 Federal
Register (80 FR 47491), we announced membership appointments to the
Panel along with the first public meeting date for the Panel, which was
held on August 26, 2015. Subsequent meetings of the Panel and
membership appointments were also announced in the Federal Register.
II. Agenda
The Agenda for the July 19 and July 20, 2023 Panel meeting will
provide for discussion and comment on the following topics as
designated in the Panel's charter:
Calendar Year (CY) 2024 Clinical Laboratory Fee Schedule
(CLFS) new and reconsidered test codes, which will be posted on the CMS
website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html.
Other CY 2024 CLFS issues designated in the Panel's
charter and further described on our Agenda.
A detailed Agenda will be posted approximately 2 weeks before the
meeting, on the CMS website at https://www.cms.gov/Regulations-and-
Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. The Panel will
make recommendations to the Secretary and the Administrator of CMS
regarding crosswalking and gapfilling for new and reconsidered
laboratory tests discussed during the CLFS Annual Public Meeting for CY
2024. The Panel will also provide input on other CY 2024 CLFS issues
that are designated in the Panel's charter and specified on the meeting
agenda.
III. Meeting Participation
This meeting is open to the public. Stand-by speakers may
participate in the meeting via teleconference and webinar. A stand-by
speaker is an individual who will speak on behalf of a company or
organization if the Panel has any questions during the meeting about
technical information described in the public comments or presentation
previously submitted or presented by the organization or company at the
recent CLFS Annual Public Meeting for CY 2023 on June 22, 2023. The
public may also view or listen-only to the meeting via teleconference
and webinar.
IV. Registration Instructions for Stand-by Speakers
Beginning May 1, 2023 and ending June 27, 2023 at 5:00 p.m. E.D.T.,
registration to serve as a stand-by speaker may be completed by sending
an email to the following resource box [email protected]. The
subject of the email should state ``Stand-by Speaker Registration for
CDLT Panel Meeting.'' In the email, all of the
[[Page 23085]]
following information must be submitted when registering:
Stand-by Speaker name.
Organization or company name.
Email addresses that will be used by the speaker in order
to connect to the virtual meeting.
New or Reconsidered Code (s) for which the company or
organization you are representing submitted a comment or presentation.
Registration details may not be revised once they are submitted. If
registration details require changes, a new registration entry must be
submitted by the date specified in the DATES section of this notice.
Additionally, registration information must reflect individual- level
content and not reflect an organization entry. Also, each individual
may only register one person at a time. That is, one individual may not
register multiple individuals at the same time.
After registering, a confirmation email will be sent upon receipt
of the registration. The email will provide information to the speaker
in preparation for the meeting. Registration is only required for
stand-by speakers and must be submitted by the deadline specified in
the DATES section of this notice. Note: No registration is required for
participants who plan to view the Panel meeting via webinar or listen
via teleconference.
V. Panel Recommendations and Discussions
The Panel's recommendations will be posted approximately 2 weeks
after the meeting on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.
VI. Special Accommodations
Individuals viewing or listening to the meeting who are hearing or
visually impaired and have special requirements, or a condition that
requires special assistance, should send an email to the resource box
([email protected]). The deadline for submitting this request is
listed in the DATES section of this notice.
VII. Copies of the Charter
The Secretary's Charter for the Medicare Advisory Panel on CDLT's
is available on the CMS website at https://cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html or you may obtain
a copy of the charter by submitting a request to the contact listed in
the FOR FURTHER INFORMATION CONTACT section of this notice.
VIII. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed
and approved this document, authorizes Evell J. Barco Holland, who is
the Federal Register Liaison, to electronically sign this document for
purposes of publication in the Federal Register.
Dated: April 11, 2023.
Evell J. Barco Holland,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2023-07913 Filed 4-13-23; 8:45 am]
BILLING CODE 4120-01-P